Top 5 Takeaways Second mRNA COVID-19 Booster’s Efficacy: In nursing home residents, a second mRNA COVID-19 booster was found to be 74% effective at 60 days against severe COVID-19 outcomes

Top 5 Takeaways Monkeypox Incidence: Among males aged 18–49 years eligible for JYNNEOS vaccination in the U.S., the incidence of monkeypox was 14 times higher among unvaccinated individuals compared to

Top 5 Takeaways Influenza vaccination coverage among Health Care Personnel (HCP) was 79.9% during the 2021–22 season. Primary COVID-19 vaccination completion was reported by 87.3% of HCP, with 67.1% of

Top 5 Takeaways Racial and ethnic disparities in influenza hospitalizations and vaccination coverage have persisted in the U.S. from 2009–10 through 2021–22, with Black, American Indian/Alaska Native (AI/AN), and Hispanic

Top 5 Takeaways Influenza A(H3N2) virus, specifically clade 3C.2a1b.2a.2, emerged in Chile much earlier than in pre-pandemic seasons, resulting in 1,002 hospitalizations in 2022. The influenza vaccination was found to

Top 5 Takeaways New and Updated Vaccine Recommendations: The 2024 immunization schedule includes key changes, notably for influenza, pneumococcal vaccines, RSV monoclonal antibody (RSV-mAb), respiratory syncytial virus vaccines (RSV), COVID-19

Top 5 Takeaways New and Updated Vaccine Recommendations: The 2024 schedule includes changes for respiratory syncytial virus (RSV), influenza, COVID-19, inactivated poliovirus vaccine (IPV), Mpox vaccine, and meningococcal vaccines. Removal

Top 5 Takeaways Bivalent mRNA COVID-19 Vaccine Effectiveness: The bivalent mRNA COVID-19 vaccine was found to be 47% effective in preventing thromboembolic events in immunocompetent persons aged ≥65 years and

Top 5 Takeaways Low Vaccination Rates Among Young Children: As of July 2022, only 4% of children aged 6 months–4 years had received at least one dose of the COVID-19